2001
Methodological Issues in Designing a Multisite Trial of Risperidone in Children and Adolescents with Autism
Scahill L, McCracken J, McDougle C, Aman M, Arnold L, Tierney E, Cronin P, Davies M, Ghuman J, Gonzalez N, Koenig K, Lindsay R, Martin A, McGough J, Posey D, Swiezy N, Volkmar F, Ritz L, Vitiello B. Methodological Issues in Designing a Multisite Trial of Risperidone in Children and Adolescents with Autism. Journal Of Child And Adolescent Psychopharmacology 2001, 11: 377-388. PMID: 11838820, DOI: 10.1089/104454601317261555.Peer-Reviewed Original ResearchConceptsPlacebo-controlled studyPlacebo-controlled discontinuation studyAutistic disorderSafety of risperidoneStudy of RisperidoneStandard pharmacological treatmentSelf-injurious behaviorDiscontinuation studyPharmacological treatmentClinical trialsInclusion criteriaLong-term effectsSevere tantrumsTrial designClinical relevanceClinical practiceLength of trialRisperidoneMultisite trialStudy designContinuous treatmentTrialsTreatment effectsDisordersMaintenance phase
1989
Whole blood serotonin and tryptophan in autism: Temporal stability and the effects of medication
Minderaa R, Anderson G, Volkmar F, Harcherick D, Akkerhuis G, Cohen D. Whole blood serotonin and tryptophan in autism: Temporal stability and the effects of medication. Journal Of Autism And Developmental Disorders 1989, 19: 129-136. PMID: 2708296, DOI: 10.1007/bf02212724.Peer-Reviewed Original ResearchConceptsWhole blood serotoninPlatelet countMedicated groupBlood serotoninSex-matched normal controlsSignificant intraclass correlation coefficientsEffects of medicationWhole blood concentrationsAutistic groupIntraclass correlation coefficientMean percentage differenceBlood concentrationsNormal controlsNormal subjectsWhole bloodTRP valuesSerotoninTryptophan valuesYear periodGroupCountPercentage differenceMedicationsBlood